Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Chronic Myeloid Leukemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01394666

CA180-240

Details and patient eligibility

About

The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.

Full description

Time Perspective: Retrospective and Prospective

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Adult patients (18 years or older) in Chronic phase CML patients who have been treated with Imatinib 400 mg and have failed.

Trial design

150 participants in 1 patient group

CP-CML patients who have failed Imatinib 400 mg daily